Umberto Eco and Pancreatic Cancer: Remembering a Literary Giant

What is on the record

Umberto Eco was born on January 5, 1932, in Alessandria, and he died on February 19, 2016, in Milan at the age of 84. He was a semiotician, a scholar of signs and meaning, before The Name of the Rose made him a household name in 1980.

The Italian news site Il Post, citing La Stampa, reported that Gianni Coscia, a lawyer and longtime friend, said he had known Eco was ill with a tumor for two years, and that Eco had last left his home in mid-January.

Beyond that, the details of his illness were private, and this article does not assert what it could not confirm. His death drew wide attention to pancreatic cancer, so the rest of this page explains what that diagnosis actually involves.

Why this cancer is found late

The pancreas sits deep in the upper abdomen, behind the stomach. Nothing presses on it early, and NCI notes that early pancreatic cancer "may not cause any signs or symptoms, making it hard to detect."

The consequence shows in the numbers. SEER, the federal statistics program, reports that 51 percent of cases have already spread to distant organs when they are found. Only 15 percent are still confined to the pancreas.

The American Cancer Society projects 67,530 new cases and 52,740 deaths in the United States in 2026, and SEER republishes both. That is 3.2 percent of new cancer diagnoses but 8.4 percent of cancer deaths. The median age at diagnosis is 71. NCI describes pancreatic cancer as the fourth leading cause of cancer death in men and the third in women.

Two different cancers, one organ

Most pancreatic cancers are exocrine, arising from the cells that make digestive enzymes. The main type is adenocarcinoma, and it is the disease this article describes.

A minority are pancreatic neuroendocrine tumors, which start in the hormone-producing islet cells. NCI reports these behave differently and carry a better outlook. They account for fewer than 2 percent of pancreatic cancers.

Symptoms, and the pattern that matters

NCI lists these signs as the disease progresses:

• Jaundice, meaning yellowing of the skin and the whites of the eyes.
• Light-colored stools.
• Dark urine.
• Pain in the upper or middle abdomen that goes through to the back.
• Weight loss for no known reason.
• Loss of appetite.
• Fatigue.

The first three belong together. A tumor in the head of the pancreas can press on the bile duct, so bile backs up. That turns the skin yellow, darkens the urine, and drains the color from stools. Jaundice without pain or fever is the classic combination, and it is the one that most often leads to an early diagnosis.

When to get checked

Book an appointment, and describe the timeline clearly, for any of these:

• Any yellowing of the skin or the whites of the eyes. Do not wait to see if it clears.
• Stools that have turned pale or clay-colored, or urine that has darkened, over a week or more.
• Upper abdominal pain that bores through to the back and has lasted more than two or three weeks, especially if lying flat makes it worse.
• Weight loss of more than about 5 percent of body weight over six months without trying.
• A new diagnosis of diabetes after age 50 that arrives alongside weight loss or abdominal pain, since NCI lists a personal history of diabetes among the risk factors.

There is no screening test for pancreatic cancer in people at average risk, and NCI has no evidence-based screening summary for it. Risk factors worth knowing include smoking, excess body weight, chronic pancreatitis, and a family history of pancreatic cancer or pancreatitis. Several inherited syndromes also raise risk, including Lynch syndrome, Peutz-Jeghers syndrome, hereditary breast and ovarian cancer syndrome, familial atypical multiple mole melanoma, and ataxia-telangiectasia. NCI's health-professional summary names the genes involved: BRCA1, BRCA2, PALB2, and ATM.

Anyone with several affected relatives should raise it with a doctor, because specialist surveillance programs exist for high-risk families.

How it is diagnosed and staged

Imaging comes first, usually a CT scan, sometimes with MRI, PET, or abdominal ultrasound. Two endoscopic procedures add detail. Endoscopic ultrasound places an ultrasound probe inside the stomach or duodenum, right next to the pancreas. ERCP examines the bile and pancreatic ducts and can relieve a blockage.

Blood tests include the tumor markers CA 19-9 and CEA. These are useful for tracking disease, not for finding it in healthy people.

Tissue confirms the diagnosis, obtained by biopsy or sometimes laparoscopy.

Staging then runs from stage 0 through stage IV, where the cancer has reached the liver, lungs, or the lining of the abdomen. Alongside the numbered stages, surgeons use a practical four-way split that determines what can be offered: resectable, meaning no involvement of major blood vessels; borderline resectable; locally advanced, where vessel invasion prevents surgery; and metastatic.

What treatment involves

Surgery offers the only chance of cure, and only for a minority. The Whipple procedure removes the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct. Total pancreatectomy and distal pancreatectomy are the alternatives, depending on where the tumor sits. NCI reports five-year survival of 18 to 24 percent after complete removal.

Chemotherapy after surgery has moved those figures. NCI reports median overall survival of 53.5 months with a combination regimen called FOLFIRINOX, compared with 35.5 months for gemcitabine alone, with five-year overall survival of 43.2 percent against 31.4 percent. Gemcitabine combined with capecitabine raised five-year survival to 28.8 percent from 16.3 percent.

Radiation, chemoradiation, and targeted therapy fill out the options. Palliative care, aimed at symptoms and quality of life, belongs in the plan from the beginning rather than at the end.

Reading the survival figures

SEER reports overall five-year relative survival of 13.7 percent for people diagnosed between 2016 and 2022. By stage it is 43.6 percent for localized disease, 17.0 percent for regional spread, and 3.4 percent for distant disease.

Those numbers are sobering, and they are also blunt instruments. They pool every subtype, every age, and every level of fitness, and they count people diagnosed years before the current regimens became standard. They describe a population. They cannot tell one person what will happen.

Sources

• https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq
• https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
• https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq
• https://seer.cancer.gov/statfacts/html/pancreas.html
• https://www.cancer.org/research/cancer-facts-statistics.html
• https://www.britannica.com/biography/Umberto-Eco
• https://www.ilpost.it/2016/02/20/umberto-eco-morto/